229 related articles for article (PubMed ID: 38200525)
1. Immunomodulation of cuproptosis and ferroptosis in liver cancer.
Mo JQ; Zhang SY; Li Q; Chen MX; Zheng YQ; Xie X; Zhang R; Wang SS
Cancer Cell Int; 2024 Jan; 24(1):22. PubMed ID: 38200525
[TBL] [Abstract][Full Text] [Related]
2. The Role of Ferroptosis and Cuproptosis in Curcumin against Hepatocellular Carcinoma.
Liu Z; Ma H; Lai Z
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838613
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Wang W; Lu K; Jiang X; Wei Q; Zhu L; Wang X; Jin H; Feng L
J Exp Clin Cancer Res; 2023 Jun; 42(1):142. PubMed ID: 37277863
[TBL] [Abstract][Full Text] [Related]
4. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma.
Yang BF; Ma Q; Hui Y; Gao XC; Ma DY; Li JX; Pei ZX; Huang BR
Transl Cancer Res; 2023 Dec; 12(12):3327-3345. PubMed ID: 38192999
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between ferroptosis and cuproptosis: From mechanism to potential clinical application.
Liu N; Chen M
Biomed Pharmacother; 2024 Feb; 171():116115. PubMed ID: 38181713
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma.
Shen Y; Li D; Liang Q; Yang M; Pan Y; Li H
Front Immunol; 2022; 13():1029092. PubMed ID: 36733399
[TBL] [Abstract][Full Text] [Related]
7. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
Li J; Liu J; Li J; Feng A; Nie Y; Yang Z; Zhang W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11647-11659. PubMed ID: 37405477
[TBL] [Abstract][Full Text] [Related]
8. Research progress in cuproptosis in liver cancer.
Chen L; Liu D; Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
[TBL] [Abstract][Full Text] [Related]
9. Molecular characteristics, clinical significance, and cancer immune interactions of cuproptosis and ferroptosis-associated genes in colorectal cancer.
Li Y; Wang RY; Deng YJ; Wu SH; Sun X; Mu H
Front Oncol; 2022; 12():975859. PubMed ID: 36132144
[TBL] [Abstract][Full Text] [Related]
10. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research.
Tong X; Tang R; Xiao M; Xu J; Wang W; Zhang B; Liu J; Yu X; Shi S
J Hematol Oncol; 2022 Dec; 15(1):174. PubMed ID: 36482419
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.
Ma J; Gong B; Zhao Q
Clin Exp Med; 2023 Dec; 23(8):4997-5014. PubMed ID: 37318649
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis and its application in different cancers: an overview.
Xu L; Liu K; Wang F; Su Y
Mol Cell Biochem; 2023 Dec; 478(12):2683-2693. PubMed ID: 36914880
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
14. Mild-Photothermal Effect Induced High Efficiency Ferroptosis-Boosted-Cuproptosis Based on Cu
Chen W; Xie W; Gao Z; Lin C; Tan M; Zhang Y; Hou Z
Adv Sci (Weinh); 2023 Nov; 10(33):e2303694. PubMed ID: 37822154
[TBL] [Abstract][Full Text] [Related]
15. Identification of biomarkers co-associated with M1 macrophages, ferroptosis and cuproptosis in alcoholic hepatitis by bioinformatics and experimental verification.
Hou S; Wang D; Yuan X; Yuan X; Yuan Q
Front Immunol; 2023; 14():1146693. PubMed ID: 37090703
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
[TBL] [Abstract][Full Text] [Related]
17. Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials.
Wang J; Li J; Liu J; Chan KY; Lee HS; Lin KN; Wang CC; Lau TS
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339263
[TBL] [Abstract][Full Text] [Related]
18. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases.
Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX
Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376
[TBL] [Abstract][Full Text] [Related]
19. A cuproptosis-related lncRNA signature for predicting prognosis and immune response in hepatocellular carcinoma.
Wu J; Yao J; Jia S; Yao X; Shao J; Cao W; Ma S; Yao X; Li H
Heliyon; 2023 Sep; 9(9):e19352. PubMed ID: 37810122
[TBL] [Abstract][Full Text] [Related]
20. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
